SAVARA INC (SVRA) Stock Fundamental Analysis

USA Nasdaq NASDAQ:SVRA • US8051111016

5.23 USD
-0.07 (-1.32%)
At close: Feb 9, 2026
5.23 USD
0 (0%)
Pre-Market: 2/10/2026, 5:59:11 AM
Fundamental Rating

2

SVRA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While SVRA seems to be doing ok healthwise, there are quite some concerns on its profitability. SVRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SVRA had negative earnings in the past year.
  • In the past year SVRA has reported a negative cash flow from operations.
  • In the past 5 years SVRA always reported negative net income.
  • In the past 5 years SVRA always reported negative operating cash flow.
SVRA Yearly Net Income VS EBIT VS OCF VS FCFSVRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • SVRA has a worse Return On Assets (-82.03%) than 68.45% of its industry peers.
  • SVRA has a Return On Equity of -122.48%. This is comparable to the rest of the industry: SVRA outperforms 40.15% of its industry peers.
Industry RankSector Rank
ROA -82.03%
ROE -122.48%
ROIC N/A
ROA(3y)-34.4%
ROA(5y)-35.67%
ROE(3y)-43.45%
ROE(5y)-47.43%
ROIC(3y)N/A
ROIC(5y)N/A
SVRA Yearly ROA, ROE, ROICSVRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • SVRA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SVRA Yearly Profit, Operating, Gross MarginsSVRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for SVRA has been increased compared to 1 year ago.
  • Compared to 5 years ago, SVRA has more shares outstanding
  • Compared to 1 year ago, SVRA has an improved debt to assets ratio.
SVRA Yearly Shares OutstandingSVRA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
SVRA Yearly Total Debt VS Total AssetsSVRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • SVRA has an Altman-Z score of 6.11. This indicates that SVRA is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 6.11, SVRA is doing good in the industry, outperforming 75.53% of the companies in the same industry.
  • A Debt/Equity ratio of 0.32 indicates that SVRA is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.32, SVRA is doing worse than 67.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z 6.11
ROIC/WACCN/A
WACCN/A
SVRA Yearly LT Debt VS Equity VS FCFSVRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • SVRA has a Current Ratio of 7.65. This indicates that SVRA is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of SVRA (7.65) is better than 73.61% of its industry peers.
  • SVRA has a Quick Ratio of 7.65. This indicates that SVRA is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 7.65, SVRA is doing good in the industry, outperforming 73.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.65
Quick Ratio 7.65
SVRA Yearly Current Assets VS Current LiabilitesSVRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

1

3. Growth

3.1 Past

  • The earnings per share for SVRA have decreased strongly by -23.26% in the last year.
EPS 1Y (TTM)-23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 26.20% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.87%
EPS Next 2Y2.08%
EPS Next 3Y16.08%
EPS Next 5Y26.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SVRA Yearly Revenue VS EstimatesSVRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2020 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
SVRA Yearly EPS VS EstimatesSVRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SVRA. In the last year negative earnings were reported.
  • Also next year SVRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SVRA Price Earnings VS Forward Price EarningsSVRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SVRA Per share dataSVRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SVRA's earnings are expected to grow with 16.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.08%
EPS Next 3Y16.08%

0

5. Dividend

5.1 Amount

  • SVRA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

SAVARA INC

NASDAQ:SVRA (2/9/2026, 8:00:01 PM)

Premarket: 5.23 0 (0%)

5.23

-0.07 (-1.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners78.43%
Inst Owner Change1.8%
Ins Owners2.15%
Ins Owner Change-1.2%
Market Cap1.06B
Revenue(TTM)N/A
Net Income(TTM)-115.60M
Analysts85.71
Price Target11.03 (110.9%)
Short Float %11.93%
Short Ratio8.21
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.07%
Min EPS beat(2)-12.66%
Max EPS beat(2)-3.49%
EPS beat(4)1
Avg EPS beat(4)-5.53%
Min EPS beat(4)-14.48%
Max EPS beat(4)8.5%
EPS beat(8)3
Avg EPS beat(8)-3.35%
EPS beat(12)6
Avg EPS beat(12)-3.68%
EPS beat(16)8
Avg EPS beat(16)-0.68%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.85%
PT rev (3m)4.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.18%
EPS NY rev (1m)0.24%
EPS NY rev (3m)0.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.27
P/tB 12.86
EV/EBITDA N/A
EPS(TTM)-0.53
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS0.46
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -82.03%
ROE -122.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.4%
ROA(5y)-35.67%
ROE(3y)-43.45%
ROE(5y)-47.43%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.63%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.65
Quick Ratio 7.65
Altman-Z 6.11
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)145.23%
Cap/Depr(5y)348.79%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-23.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.27%
EPS Next Y-11.87%
EPS Next 2Y2.08%
EPS Next 3Y16.08%
EPS Next 5Y26.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.72%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-123.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-124.39%
OCF growth 3YN/A
OCF growth 5YN/A

SAVARA INC / SVRA FAQ

Can you provide the ChartMill fundamental rating for SAVARA INC?

ChartMill assigns a fundamental rating of 2 / 10 to SVRA.


What is the valuation status for SVRA stock?

ChartMill assigns a valuation rating of 0 / 10 to SAVARA INC (SVRA). This can be considered as Overvalued.


What is the profitability of SVRA stock?

SAVARA INC (SVRA) has a profitability rating of 0 / 10.


How financially healthy is SAVARA INC?

The financial health rating of SAVARA INC (SVRA) is 5 / 10.